Treatment of Non-Metastatic Hepatocellular Carcinoma in Humans by Increasing Gabaergic Activity: A Pilot Study
Status:
Withdrawn
Trial end date:
2011-01-01
Target enrollment:
Participant gender:
Summary
Recent studies indicate that liver cancer cells possess a receptor called the GABA-B receptor
that when activated, inhibits the spread of cancer cells in test tubes. One of the drugs that
activate these receptors is Baclofen, an agent that was originally developed to treat
patients with various neurologic disorders. In this study, patients with recently identified
liver cancer will be treated with Baclofen in an attempt to prevent or delay spread of the
cancer beyond the liver. The time it takes for liver cancer to spread in the patients will be
compared to the results obtained from patients enrolled in previous studies where Baclofen
was not used.